Impaired Esophageal Mucosal Integrity May Play a Causative Role in Patients With Nongastroesophageal Reflux Disease–Related Noncardiac Chest Pain

Yang Won Min, MD, PhD, Kyu Choi, MD, Jeung Hui Pyo, MD, Hee Jung Son, MD, PhD, and Poong-Lyul Rhee, MD, PhD

Abstract: Baseline impedance (BI) measurement can be used to evaluate the status of the esophageal mucosa integrity. We hypothesized that impaired esophageal mucosal integrity may play a causative role in patients with nongastroesophageal reflux disease (non-GERD)–related noncardiac chest pain (NCCP). This retrospective study analyzed 24-hour multichannel intraluminal impedance-pH testing data from 77 patients with NCCP and 5 healthy volunteers. BI was calculated at 3 cm (distal esophagus) and 17 cm (proximal esophagus) above the lower esophageal sphincter. GERD was defined by the presence of pathologic acid exposure or reflux esophagitis. Among the 77 patients with NCCP, 16 (20.8%) were classified into the GERD-related NCCP group and 61 (79.2%) into the non-GERD-related NCCP group. BI (median, interquartile range) of the non-GERD-related NCCP group was lower than the control group at the proximal esophagus (2507 ± 1998 vs 3855 ± 1619, P = 0.001) but was similar at the distal esophagus. The GERD-related NCCP group showed lower BI than the control group at both the distal and proximal esophagus (2024 ± 1112 vs 3203 ± 2306, 2366 ± 3774 vs 1896 ± 2908 vs 3855 ± 1619, 3238 ± 4182, P = 0.003, respectively). At the distal esophagus, BI was lower in the GERD-related NCCP group than the non-GERD-related NCCP group (P = 0.002), whereas it did not differ between the 2 groups at the proximal esophagus. In conclusion, the mucosal integrity is impaired at the proximal esophagus in patients with non-GERD-related NCCP, which might be the pathogenic mechanism of NCCP.

(INTRODUCTION)

Noncardiac chest pain (NCCP) is defined as recurrent episodes of substernal chest pain that does not originate from cardiac cause.1 The prevalence of NCCP is reported as 19% to 33%,2–5 and it affects 23% of the population during lifetime.6 Although NCCP has excellent long-term prognosis, most of the patients with NCCP suffer from their symptom persistently.6 However, determining the clear etiology for patients with NCCP remains a challenge.7 Several pathophysiological mechanisms have been suggested, including gastroesophageal reflux disease (GERD), esophageal motility disorder, esophageal visceral hypersensitivity, and psychological comorbidity.7 Among them, GERD is the most common cause of NCCP.3,4 It is present in up to 60% of patients with NCCP in Western countries and ~35% in Asia.10–12 Esophageal motility disorder can be considered as an etiology of NCCP especially in non-GERD-related NCCP.13 Approximately 30% of patients with non-GERD-related NCCP are diagnosed as an esophageal motility disorder through esophageal manometric evaluation.13 Nevertheless, the etiology of NCCP still remains unclear in a significant portion of patients with NCCP. Esophageal visceral hypersensitivity is regarded as the presumed remaining etiology.13 Indeed, visceral hypersensitivity has been one of the most important pathophysiologic mechanisms in functional gastrointestinal disorders.14,16

Over the last decade, the impairment of the esophageal mucosa integrity has become apparent to play a role in symptom perception in nonerosive reflux disease (NERD).17 This has prompted the hypothesis that impaired esophageal mucosal integrity may also play a causative role in NCCP, especially in non-GERD-related cases. Recently, baseline impedance (BI) measurement at the esophageal mucosa using 24-hour multichannel intraluminal impedance-pH testing (24-hr MII-pH) has been used to evaluate the status of the esophageal mucosa integrity.18 Impaired esophageal mucosa integrity morphologically displays the dilated intercellular spaces, which are the consequence of acid-peptic injury.19,20 If the mucosa is more permeable to ionic flow due to dilated intercellular spaces, BI will be lower. Thus, to test our hypothesis, we evaluated BI in the patients with NCCP and controls, and compared clinical data regarding esophageal high-resolution impedance-manometry (HRIM), 24-hr MII-pH, and upper endoscopy in patients with NCCP and control groups.

METHODS

Subjects

We performed a retrospective review of patients who were diagnosed with NCCP at the Samsung Medical Center between June 2011 and December 2012. All the patients presented with angina-like chest pain and underwent a cardiologic evaluation...
such as electrocardiogram, echocardiogram, exercise treadmill test, and stress thallium scan depending on the patient’s condition. After cardiac disease had been ruled out, patients underwent esophageal workup including upper endoscopy, esophageal HRIM, and 24-hr MII-pH. The patients with peptic ulcer disease, infectious esophagitis, a history of gastrointestinal surgery, and psychiatric disorders (e.g., depression, panic disorder, and anxiety disorder) with medication were excluded.

For control, 5 healthy volunteers (2 men, ages 28–31 years) were recruited. They denied any symptoms of gastrointestinal system and any history of medical disease. All the volunteers revealed normal results on upper endoscopy, esophageal HRIM, and 24-hr MII-pH. This study protocol was conducted in accordance with the Declaration of Helsinki and approved by the institutional review board of Samsung Medical Center, Seoul, Korea (no. 2014-11-038).

Esophageal High-Resolution Manometry Protocol

High-resolution manometry (HRM) was performed in the standard fashion with a series of 10 swallows of 5-mL normal saline each in a supine, using the HRIM system (Sandhill Scientific, Highlands Ranch, CO). The motility disorders and peristalsis abnormalities were defined by the Chicago classification version 3.0. All the measurements were analyzed by using BioVIEW Analysis software (Sandhill Scientific) and were also reviewed manually.

24-hr MII-pH Protocol

Patients were instructed to stop proton pump inhibitor (PPI) and H2 receptor antagonist prior to the study ≥7 and 3 days, respectively. 24-hr MII-pH was performed after stationary HRM, using the ZepHr system (Sandhill Scientific). In this system, the pH is measured at 5 cm above the lower esophageal sphincter (LES), and the impedance levels are measured at 3, 5, 7, 9, 15, and 17 cm above the LES. The BioVIEW Analysis software (Sandhill Scientific) was used for data analysis, and the process was also reviewed manually.

BI Measurement

BI was calculated at 3 cm (distal BI) and 17 cm (proximal BI) above the LES by K.C., who was blinded to the patient groups. The 24-hr full-traced impedance recording was divided into 4 periods according to meals and sleep (2 periods between meals and 2 periods before and during sleep). In each period, we selected 3 different 1-minute duration measures, that had a constantly stable impedance level, for impedance measurement. Impedance of each period was calculated by averaging these 3 impedance levels. Then, BI was calculated by averaging the 4 period impedance levels (Fig. 1).

Definitions

Pathologic acid exposure (PAE) and pathologic bolus exposure (PBE) were defined as an intraesophageal pH of <4 for >4.2% of the recording time and as refluxate in contact with distal impedance electrodes for >1.4% of the recording time, respectively. Impaired bolus transit (IBT) was defined as >20% of swallows with incomplete bolus transit. GERD was defined by the presence of PAE or reflux esophagitis (RE, at least grade A according to the Los Angeles classification) on the upper endoscopy.

Statistical Analysis

Shapiro–Wilk test was performed for normality. The statistical results were presented as median with interquartile

---

**FIGURE 1.** BI measurement protocol. At each time period, 3 different measures of 1-minute duration with constantly stable impedance level were selected for impedance measurement. Impedance of each period was calculated by averaging these 3 impedance levels. Then, BI was calculated by averaging the 4 period impedance levels. Proximal and distal esophageal BI was measured at 17 and 3 cm above the LES, respectively. BI = baseline impedance, GERD = gastroesophageal reflux disease, LES = lower esophageal sphincter.
RESULTS

Demographics and Clinical Characteristics

A total of 77 patients with NCCP were included in the present study. Among them, 16 patients (20.8%) were classified into the GERD-related NCCP group and 61 (79.2%) into the non-GERD-related NCCP group. As shown in Table 1, there were no significant differences between the GERD-related NCCP and non-GERD-related NCCP groups regarding age, sex, HRM metrics including distal contractile integral, integrated relaxation pressure, and distal latency, complete bolus transit, IBT rate, presence of peristaltic disorders, and previous history of PPI treatment. However, the GERD-related NCCP group showed longer acid (5.2%, IQR 1.325–8.425 vs 0.3%, IQR 0.0–1.1, P < 0.001) and bolus (1.95%, IQR 0.9–3.125 vs 0.8%, IQR 0.3–0.8, P = 0.003) exposure time and more frequent PAE (62.5% vs 0%, P < 0.001), PBE (62.5% vs 24.6%, P = 0.004), and RE (56.3% vs 0%, P < 0.001) than the non-GERD-related NCCP group.

Baseline Impedance

BI at the distal esophagus was compared between the GERD-related NCCP, non-GERD-related NCCP, and control groups (Fig. 2A). BI did not significantly differ between the non-GERD-related NCCP and control groups (2507 Ω, IQR 2156–3217 vs 3203 Ω, IQR 2366–3774, P = 0.245). However, the GERD-related NCCP group (2024 Ω, IQR 1619–2308) showed lower BI than the non-GERD-related NCCP and control groups (P = 0.002 and P = 0.007, respectively). As shown in Figure 2B, BI of the non-GERD-related NCCP group was lower than the control group at the proximal esophagus (2507 Ω, IQR 2156–3217 vs 3855 Ω, IQR 3238–4182, P = 0.001) but was similar to the GERD-related NCCP group (2272 Ω, IQR 1896–2908, P = 0.629). The GERD-related NCCP group also showed lower BI than the control group at the proximal esophagus (P = 0.003).

Effect of Age on BI

In the 77 patients with NCCP, median age was 58 years. Thus, BI was compared between the 2 age groups (age <60 vs ≥60 years). However, BI did not differ by age at both distal and proximal esophagus (Fig. 3).

DISCUSSION

Despite a significant medicosocial burden of NCCP,26–28 its pathophysiological mechanisms behind symptom generation remain to be elucidated. Esophageal visceral hypersensitivity has been demonstrated in most of the patients with non-GERD-related NCCP regardless of the presence of esophageal motility disorder.1 Over the last decade, the impairment of esophageal mucosal integrity has become apparent to explain the symptom generation in the macroscopically normal mucosa in NERD.17,19,29 However, the role of esophageal mucosal integrity in NCCP has not been investigated. Thus, we conducted the first study to test our hypothesis that impaired esophageal mucosal integrity may also play a causative role in the non-GERD-related NCCP.

**TABLE 1.** Comparison of Baseline Characteristics between the GERD-related NCCP and non-GERD-related NCCP Groups

| Variables                                      | GERD (n = 16) | Non-GERD (n = 61) | P      |
|------------------------------------------------|--------------|------------------|--------|
| Demographics                                   |              |                  |        |
| Age, y                                         | 60 (53.25–66)| 58 (52–63)       | 0.255  |
| Sex, male                                      | 5 (31.3)     | 23 (37.7)        | 0.633  |
| HRM metrics                                    |              |                  |        |
| Distal contractile integral, mm Hg-s-cm        | 1254 (965–2036.75) | 1453 (768–2218.5) | 1.000  |
| Integrated relaxation pressure, mm Hg          | 10 (7.25–12.5)| 12 (9.0–15.0)    | 0.075  |
| Distal latency, s                              | 5.85 (4.525–6.475)| 5.6 (4.65–6.5)  | 0.763  |
| Complete bolus transit, liquid, %              | 40 (32.5–65) | 20 (10–73.5)     | 0.419  |
| Impaired bolus transit                         | 13 (81.3)    | 47 (77.0)        | 0.053  |
| Peristaltic disorders in the CC version 3.0    |              |                  |        |
| Major disorders                                | 1 (6.3)      | 5 (8.2)          | 0.451  |
| Minor disorders                                | 2 (12.5)     | 9 (14.8)         | 0.230  |
| 24-hr MII-pH                                    |              |                  |        |
| Acid exposure time, pH <4.0, %                 | 5.2 (1.325–8.425)| 0.3 (0.0–1.1)   | <0.001 |
| PAE                                            | 10 (62.5)    | 0 (0)            | <0.001 |
| Bolus exposure time, %                         | 1.95 (0.9–3.125)| 0.8 (0.3–0.8)  | 0.003  |
| PBE                                            | 10 (62.5)    | 15 (24.6)        | 0.004  |
| RE                                             | 9 (56.3)     | 0 (0)            | <0.001 |
| History of PPI treatment                       | 8 (50.0)     | 20 (32.8)        | 0.089  |

Data are shown as the median (IQR) or number (%) of patients. 24-hr MII-pH = 24-hour multichannel intraluminal impedance-pH monitoring, CC = Chicago classification, GERD = gastroesophageal reflux disease, HRM = high-resolution manometry, IBT = impaired bolus transit, IQR = interquartile range, NCCP = noncardiac chest pain, PAE = pathologic acid exposure, PBE = pathologic bolus exposure, PPI = proton pump inhibitor, RE = reflux esophagitis.
The GERD-related NCCP group showed lower BI than the control group at both distal and proximal esophagus. This observation is consistent with those of previous studies. Kessing et al. demonstrated that BI is related to esophageal acid exposure, where BI at both distal and proximal esophagus in GERD patients with pathologic acid reflux was lower than in controls. In a study by Kandulski et al., BI was compared between patients with functional heartburn (FH) and GERD. At the distal esophagus, BI was significantly lower in patients with erosive reflux disease (ERD) or NERD than those with FH. However, reduced BI levels were found only in patients with ERD at the proximal esophagus. As the patients with GERD-related NCCP were defined by the presence of PAE and/or RE in the present study, they seem to show lower BI at both distal and proximal esophagus than controls, indicating an impaired mucosal integrity along the whole esophagus.

Of interest, BI of the non-GERD-related NCCP group was significantly lower than the control group at the proximal esophagus but not at the distal esophagus. The GERD-related NCCP group showed lower BI than the control group at both distal and proximal esophagus. Whisker extends to the minimum and maximum values. BI = baseline impedance, GERD = gastroesophageal reflux disease, NCCP = noncardiac chest pain.

**FIGURE 2.** BI between groups at the distal and proximal esophageal mucosa. Note that BI of the non-GERD-related NCCP group was lower than the control group at the proximal esophagus but not at the distal esophagus. The GERD-related NCCP group showed lower BI than the control group at both distal and proximal esophagus. Whisker extends to the minimum and maximum values. BI = baseline impedance, GERD = gastroesophageal reflux disease, NCCP = noncardiac chest pain.

**FIGURE 3.** Comparison of BI according to age in patients with NCCP. Among 77 patients with NCCP, BI did not differ by age (age < 60 vs ≥ 60 years) at both distal and proximal esophageal mucosa. Whisker extends to the minimum and maximum values. BI = baseline impedance, NCCP = noncardiac chest pain.

ERD at the proximal esophagus. As the patients with GERD-related NCCP were defined by the presence of PAE and/or RE in the present study, they seem to show lower BI at both distal and proximal esophagus than controls, indicating an impaired mucosal integrity along the whole esophagus.

Of interest, BI of the non-GERD-related NCCP group was significantly lower than the control group at the proximal esophagus. However, BI of the non-GERD-related NCCP group was higher than the GERD-related NCCP group and was similar to the control group at the distal esophagus. As the mucosa is more permeable to ionic flow due to dilated intercellular spaces, BI will be lowered when the esophageal mucosa integrity is impaired. Thus, our results indicate that the esophageal mucosa integrity may be impaired at the proximal esophagus in patients with non-GERD-related NCCP. The impaired mucosal integrity...
renders the mucosa more vulnerable to symptomatic perception.22–34 Indeed, in a recent study including patients with NERD or FH, those with lower BI were more likely to painfully perceive the acid perfusion.33 Once mucosal injury occurs, several inflammatory mediators are released in response to a variety of noxious stimuli. These mediators have the common effect of reducing the transduction threshold of a variety of cation channels on primary afferent myelinated or unmyelinated neurons.35 In real life, it is possible that we are highly exposed to intake capable of disruption of the esophageal mucosal integrity by chemical, thermal, or mechanical injury, which could include many things besides refluxate such as hot tea and coffee, carbonated drinks, alcohols, spicy and salty foods, and drugs.36,37 Even acute stress could cause the impairment of esophageal mucosal integrity with a subsequent visceral hypersensitivity.38 In a recent experimental study by Zhang et al.,39 mast cell activation impaired the esophageal mucosal integrity, which subsequently increased esophageal vagal nociceptive C fiber activation. Taken together, the impaired esophageal mucosal integrity at the proximal esophagus may play a causative role in the non-GERD-related NCCP. Plausible scenario is that patients with non-GERD-related NCCP received certain injuries that could be repetitive and subsequently develop impaired esophageal mucosal integrity, resulting in frequent symptom perception from various stimuli. To confirm our results, further studies to evaluate the effect of restoring the proximal esophageal mucosal integrity on the symptom relief in patients with non-GERD-related NCCP are warranted.

The present study had some limitations. First, the control group was rather small and consisted of younger patients than the NCCP groups. However, BI of the control group was similar to that of the previous study.41 In addition, BI of the non-GERD-related NCCP group was similar to that of GERD-related NCCP group at the proximal esophagus, whereas BI of the non-GERD-related NCCP group was rather small and consisted of younger patients than the control group. Instead, our findings came from the comparisons of BI between the groups. Thus, the interobserver agreement was not measured. Third, we did not confirm histologically dilated intercellular spaces in the NCCP groups, although BI measured by 1 investigator, resulting in a possible bias. Therefore, our findings are based on the comparisons of BI between groups. Further studies to evaluate the functional and morphologic integrity of the esophageal mucosa in patients with non-GERD-related NCCP are warranted to confirm our findings.

REFERENCES

1. Fass R, Achem SR. Noncardiac chest pain: epidemiology, natural course and pathogenesis. J Neurogastroenterol Motil. 2011;17:110–123.

2. Locke GR 3rd, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology. 1997;112:1448–1456.

3. Ellisck GD, Jones MP, Talley NJ. Non-cardiac chest pain: prevalence, risk factors, impact and consulting—a population-based study. Aliment Pharmacol Ther. 2003;17:1115–1124.

4. Wong WM, Lai KC, LamKF, et al. Prevalence, clinical spectrum and health care utilization of gastro-esophageal reflux disease in a Chinese population: a population-based study. Aliment Pharmacol Ther. 2003;18:595–604.

5. Chiocca JC, Olmos JA, Salis GB, et al. Prevalence, clinical spectrum and atypical symptoms of gastro-oesophageal reflux in Argentina: a nationwide population-based study. Aliment Pharmacol Ther. 2005;22:331–342.

6. Potts SG, Bass CM. Psychological morbidity in patients with chest pain and normal or near-normal coronary arteries: a long-term follow-up study. Psychol Med. 1995;25:339–347.

7. Hershcovici T, Achem SR, Jha LK, et al. Systematic review: the treatment of noncardiac chest pain. Aliment Pharmacol Ther. 2012;35:5–14.

8. Van Handel D, Fass R. The pathophysiology of non-cardiac chest pain. J Gastroenterol Hepatol. 2005;20(suppl):S6–S13.

9. Kim JH, Rhee PL. Recent advances in noncardiac chest pain in Korea. Gut Liver. 2012;6:1–9.

10. Richter JE. Chest pain and gastroesophageal reflux disease. J Clin Gastroenterol. 2000;30(3 suppl):S39–S41.

11. Wong WM, Lai KC, Lau CP, et al. Upper gastrointestinal evaluation of Chinese patients with non-cardiac chest pain. Aliment Pharmacol Ther. 2002;16:465–471.

12. Kim JH, Rhee PL, Park EH, et al. Clinical usefulness of subgrouping of patients with non-cardiac chest pain according to characteristic symptoms in Korea. J Gastroenterol Hepatol. 2007;22:320–325.

13. Fass R, Navarro-Rodriguez T. Noncardiac chest pain. J Clin Gastroenterol. 2008;42:636–646.

14. Katz PO, Dalton CB, Richter JE, et al. Esophageal testing of patients with noncardiac chest pain or dysphagia. Results of three years’ experience with 1161 patients. Ann Intern Med. 1987;106:593–597.

15. Bouin M, Plourde V, Boivin M, et al. Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds. Gastroenterology. 2002;122:1771–1777.

16. Miwa H, Kondo T, Oshima T, et al. Esophageal sensation and esophageal hypersensitivity—overview from bench to bedside. J Neurogastroenterol Motil. 2010;16:353–362.

17. Woodland P, Sifrim D. Esophageal mucosal integrity in non erosive reflux disease. J Clin Gastroenterol. 2014;48:6–12.

18. Farre R, Blondeau K, Clement D, et al. Evaluation of oesophageal mucosa integrity by the intraluminal impedance technique. Gut. 2011;60:885–892.

19. Caviglia R, Ribolzi M, Gentile M, et al. Dilated intercellular spaces and acid reflux at the distal and proximal oesophagus in patients with non-erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2007;25:629–636.

20. Tobey NA, Hosseinli SS, Caymaz-Bor C, et al. The role of pepsin in acid injury to esophageal epithelium. Am J Gastroenterol. 2001;96:3062–3070.

21. Kahalas PJ, Bredenoord AJ, Fox M, et al. The Chicago Classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil. 2015;27:160–174.

22. Shay S, Tutuian R, Sifrim D, et al. Twenty-four hour ambulatory simultaneous impedance and pH monitoring: a multicenter report of normal values from 60 healthy volunteers. Am J Gastroenterol. 2004;99:1037–1043.
23. Sifrim D, Castell D, Dent J, et al. Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux. *Gut*. 2004;53:1024–1031.

24. Tutuian R, Vela MF, Balaji NS, et al. Esophageal function testing with combined multichannel intraluminal impedance and manometry: multicenter study in healthy volunteers. *Clin Gastroenterol Hepatol*. 2003;1:174–182.

25. Armstrong D, Bennett JR, Blum AL, et al. The endoscopic assessment of esophagitis: a progress report on observer agreement. *Gastroenterology*. 1996;111:85–92.

26. Eslick GD. Noncardiac chest pain: epidemiology, natural history, health care seeking, and quality of life. *Gastroenterol Clin North Am*. 2004;33:1–23.

27. Karlson BW, Wiklund I, Bengtson A, et al. Prognosis, severity of symptoms, and aspects of well-being among patients in whom myocardial infarction was ruled out. *Clin Cardiol*. 1994;17:427–431.

28. Eslick GD, Talley NJ. Non-cardiac chest pain: squeezing the life out of the Australian healthcare system? *Med J Aust*. 2000;173:233–234.

29. Caviglia R, Ribolsi M, Maggiano N, et al. Dilated intercellular spaces of esophageal epithelium in nonerosive reflux disease patients with physiological esophageal acid exposure. *Am J Gastroenterol*. 2005;100:543–548.

30. Kandulski A, Weigt J, Caro C, et al. Esophageal intraluminal baseline impedance differentiates gastroesophageal reflux disease from functional heartburn. *Clin Gastroenterol Hepatol*. 2015;13:1075–1081.

31. Kessing BF, Bredenoord AJ, Weijenborg PW, et al. Esophageal acid exposure decreases intraluminal baseline impedance levels. *Am J Gastroenterol*. 2011;106:2093–2097.

32. Ribolsi M, Perrone G, Caviglia R, et al. Intercellular space diameters of the oesophageal epithelium in NERD patients: head to head comparison between light and electron microscopy analysis. *Dig Liver Dis*. 2009;41:9–14.

33. Woodland P, Al-Zinaty M, Yazaki E, et al. In vivo evaluation of acid-induced changes in oesophageal mucosa integrity and sensitivity in non-erosive reflux disease. *Gut*. 2013;62:1256–1261.

34. Weijenborg PW, Smout AJ, Verweijden C, et al. Hypersensitivity to acid is associated with impaired esophageal mucosal integrity in patients with gastroesophageal reflux disease with and without esophagitis. *Am J Physiol Gastrointest Liver Physiol*. 2014;307:G323–G329.

35. Knowles CH, Aziz Q. Visceral hypersensitivity in non-erosive reflux disease. *Gut*. 2008;57:674–683.

36. Lanas A, Hirschowitz BI. Significant role of aspirin use in patients with esophagitis. *J Clin Gastroenterol*. 1991;13:622–627.

37. Gebhart GF. Peripheral contributions to visceral hyperalgesia. *Can J Gastroenterol*. 1999;13(suppl A):37A–41A.

38. Farre R, De Vos R, Geboes K, et al. Critical role of stress in increased oesophageal mucosa permeability and dilated intercellular spaces. *Gut*. 2007;56:1191–1197.

39. Zhang S, Liu Z, Heldsinger A, et al. Intraluminal acid activates esophageal nodose C fibers after mast cell activation. *Am J Physiol Gastrointest Liver Physiol*. 2014;306:G200–G207.